Ouro Medicines Achieves FDA Fast Track Designation for Gamgertamig in Treating Serious Autoimmune Diseases Ouro Medicines has received U.S. FDA Fast Track designation for Gamgertamig, aimed at treating life-threatening autoimmune disorders like ITP and AIHA.

Ouro Medicines Achieves FDA Fast Track Designation for Gamgertamig in Treating Serious Autoimmune Diseases #United_States #FDA #South_San_Francisco #Ouro_Medicines #Gamgertamig

Ouro Medicines Achieves FDA Orphan Drug Designation for Gamgertamig in Treating Immune Thrombocytopenia Ouro Medicines secures FDA Orphan Drug Designation for Gamgertamig, aimed at treating immune thrombocytopenia. This marks a significant milestone in its development process.

Ouro Medicines Achieves FDA Orphan Drug Designation for Gamgertamig in Treating Immune Thrombocytopenia #United_States #South_San_Francisco #Ouro_Medicines #FDA_Orphan_Drug #Gamgertamig

Ouro Medicines Expands Clinical Development of OM336 for Sjögren's Disease and IIM Ouro Medicines has officially announced the expansion of its clinical development for OM336, targeting Sjögren's disease and idiopathic inflammatory myopathy, promising new hope for patients.

Ouro Medicines Expands Clinical Development of OM336 for Sjögren's Disease and IIM #United_States #South_San_Francisco #Ouro_Medicines #Sjögren's_Disease #OM336

Ouro Medicines Launches OM336 Study for Autoimmune Cytopenias with FDA Orphan Status Ouro Medicines has initiated a clinical study of OM336 for autoimmune cytopenias and received the FDA’s Orphan Drug Designation for AIHA.

Ouro Medicines Launches OM336 Study for Autoimmune Cytopenias with FDA Orphan Status #USA #San_Francisco #Ouro_Medicines #Autoimmune_Diseases #OM336

Ouro Medicines Takes a Bold Step in Autoimmune Treatment with New Clinical Trial for OM336 Ouro Medicines announces plans for a clinical trial of OM336, aimed at tackling autoimmune cytopenias. Exciting case studies emerge in NEJM, advocating the potential of this therapy.

Ouro Medicines Takes a Bold Step in Autoimmune Treatment with New Clinical Trial for OM336 #United_States #San_Francisco #Ouro_Medicines #OM336 #Autoimmune_Cytopenias

Ouro Medicines Unveils Innovative Treatments for Immune-Mediated Disorders Ouro Medicines has just launched, backed by $120 million funding, aiming to revolutionize immune-mediated disease treatment through groundbreaking T cell therapies.

Ouro Medicines Unveils Innovative Treatments for Immune-Mediated Disorders #United_States #San_Francisco #biotechnology #Ouro_Medicines #T_cell_engagers